Navigation Links
Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
Date:6/1/2011

SAN DIEGO, June 1, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced issuance of the U.S. patent covering setrobuvir (ANA598), the Company's Direct-Acting Antiviral (DAA) in Phase IIb development for chronic hepatitis C virus infection (HCV).  U.S. Patent No. 7,939,524, granted to Anadys by the United States Patent and Trademark Office, recognizes the Company's intellectual property rights to the composition of matter and methods of use for setrobuvir (ANA598) and related compounds.  

"Securing U.S. patent protection is a critical step that significantly enhances the value of setrobuvir," said Steve Worland, Ph.D., President and CEO of Anadys.  "This milestone comes at an important juncture in the setrobuvir development program, as we complete enrollment of our Phase IIb trial and begin the investigation of setrobuvir in combination with other DAAs."

About Setrobuvir (ANA598)

Setrobuvir (ANA598), the Company's wholly-owned DAA, is currently in Phase IIb testing in combination with pegylated interferon and ribavirin for the treatment of HCV.  Anadys recently announced a cross-company clinical trial agreement with a large, commercial-stage biopharmaceutical company to study setrobuvir (ANA598) in combination with another DAA in healthy volunteers.  Setrobuvir is the name recently adopted for ANA598 by the United States Adopted Names (USAN) Council.

Setrobuvir (ANA598) is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.  Setrobuvir has a well-characterized safety database in which more than 150 subjects have received the agent to date.  Setrobuvir (ANA598) has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

About the Phase IIb Study of Setrobuvir (ANA598)

In the ongoing Phase IIb study, setrobuvir (ANA598) is being tested in combination with Pegasys® and Copegus® in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Dosing is underway and approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  

Prior Clinical and Preclinical Profile of Setrobuvir (ANA598)

In an earlier Phase IIa study, setrobuvir (ANA598) demonstrated potent antiviral activity, as well as good safety and tolerability in combination with interferon and ribavirin through 12 weeks of dosing in treatment-naive genotype 1 HCV patients.  In a completed Phase I study, setrobuvir demonstrated potent antiviral activity in a three day monotherapy study in treatment-naive genotype 1 patients.  To date, setrobuvir has demonstrated an excellent resistance profile in HCV patients.

Setrobuvir (ANA598) has also been characterized in a variety of preclinical studies.  In completed long-term chronic toxicology tests in both rats and monkeys, the No Observed Adverse Effect Level, or NOAEL, was 1000 mg/kg, the highest dose tested.  Data from preclinical models of antiviral activity have laid the foundation for clinical investigation of setrobuvir (ANA598) in DAA combinations.  In particular, synergistic antiviral activity in vitro was observed when setrobuvir (ANA598) was combined with a number of approved or investigational HCV agents, and in vitro combinations of setrobuvir (ANA598) with other DAAs from multiple classes resulted in clearance of HCV RNA from cells rather than selection of resistant isolates.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the timing, occurrence and outcome of expected data events from the setrobuvir (ANA598) Phase IIb study; (ii) the clinical and preclinical profile of setrobuvir (ANA598) based on data received to date; and (iii) predictions regarding the transferability of preclinical models of DAA combinations with setrobuvir (ANA598) to clinical investigation, as well as the occurrence, timing and outcome of such clinical investigation.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that setrobuvir (ANA598) will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.   In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended March 31, 2011.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Pegasys® and Copegus® are registered trademarks of Hoffman-La Roche Inc.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
2. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
3. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
5. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
6. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
7. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
8. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
10. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):